Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced data from a Phase 2 study of ISIS-APOCIIIRx as a monotherapy in patients with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE